Repare Net Receivables vs Accounts Payable Analysis

RPTX Stock  USD 2.81  0.16  5.39%   
Repare Therapeutics financial indicator trend analysis is much more than just breaking down Repare Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Repare Therapeutics is a good investment. Please check the relationship between Repare Therapeutics Net Receivables and its Accounts Payable accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repare Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Repare Stock please use our How to Invest in Repare Therapeutics guide.

Net Receivables vs Accounts Payable

Net Receivables vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Repare Therapeutics Net Receivables account and Accounts Payable. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Repare Therapeutics' Net Receivables and Accounts Payable is 0.58. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Repare Therapeutics, assuming nothing else is changed. The correlation between historical values of Repare Therapeutics' Net Receivables and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Repare Therapeutics are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Net Receivables i.e., Repare Therapeutics' Net Receivables and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.58
Relationship DirectionPositive 
Relationship StrengthWeak

Net Receivables

Accounts Payable

An accounting item on the balance sheet that represents Repare Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Repare Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.
Most indicators from Repare Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Repare Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repare Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Repare Stock please use our How to Invest in Repare Therapeutics guide.Tax Provision is likely to drop to about 2.8 M in 2024. Selling General Administrative is likely to drop to about 18.4 M in 2024
 2021 2022 2023 2024 (projected)
Reconciled Depreciation1.5M2.0M1.9M1.2M
Total Operating Expenses116.3M151.6M167.4M84.1M

Repare Therapeutics fundamental ratios Correlations

0.920.830.780.850.510.860.88-0.78-0.840.560.80.860.620.530.910.70.870.070.870.880.730.680.850.90.92
0.920.840.80.980.680.950.98-0.91-0.820.470.930.950.50.681.00.610.93-0.130.860.990.660.490.980.911.0
0.830.840.910.870.280.910.86-0.61-0.930.320.640.850.660.460.830.690.92-0.430.940.840.840.240.870.940.84
0.780.80.910.80.160.80.79-0.52-0.820.00.550.730.460.310.80.520.82-0.40.850.770.740.340.80.780.81
0.850.980.870.80.670.980.96-0.88-0.820.420.90.940.490.660.980.610.94-0.30.840.990.660.311.00.920.98
0.510.680.280.160.670.610.67-0.91-0.230.60.870.690.010.820.680.140.460.260.280.710.010.370.670.510.68
0.860.950.910.80.980.610.93-0.83-0.860.470.840.920.570.610.950.670.95-0.330.870.970.720.260.980.960.95
0.880.980.860.790.960.670.93-0.91-0.820.50.930.990.490.780.970.570.92-0.150.870.970.640.460.960.920.97
-0.78-0.91-0.61-0.52-0.88-0.91-0.83-0.910.56-0.6-0.99-0.91-0.25-0.87-0.91-0.37-0.74-0.12-0.62-0.91-0.34-0.51-0.88-0.77-0.91
-0.84-0.82-0.93-0.82-0.82-0.23-0.86-0.820.56-0.45-0.63-0.81-0.86-0.36-0.81-0.89-0.960.41-0.99-0.81-0.96-0.27-0.82-0.93-0.81
0.560.470.320.00.420.60.470.5-0.6-0.450.620.580.560.580.450.580.480.320.440.490.370.390.420.60.46
0.80.930.640.550.90.870.840.93-0.99-0.630.620.930.360.840.930.470.80.060.690.930.440.510.90.80.93
0.860.950.850.730.940.690.920.99-0.91-0.810.580.930.510.820.950.590.91-0.130.870.950.640.440.940.940.95
0.620.50.660.460.490.010.570.49-0.25-0.860.560.360.510.070.480.980.75-0.350.790.510.930.110.490.70.5
0.530.680.460.310.660.820.610.78-0.87-0.360.580.840.820.070.680.120.520.170.460.680.120.390.660.620.67
0.911.00.830.80.980.680.950.97-0.91-0.810.450.930.950.480.680.60.92-0.130.850.990.650.50.980.91.0
0.70.610.690.520.610.140.670.57-0.37-0.890.580.470.590.980.120.60.82-0.340.820.630.940.160.610.760.61
0.870.930.920.820.940.460.950.92-0.74-0.960.480.80.910.750.520.920.82-0.380.960.940.870.280.940.960.93
0.07-0.13-0.43-0.4-0.30.26-0.33-0.15-0.120.410.320.06-0.13-0.350.17-0.13-0.34-0.38-0.35-0.21-0.480.71-0.3-0.26-0.13
0.870.860.940.850.840.280.870.87-0.62-0.990.440.690.870.790.460.850.820.96-0.350.840.920.340.840.930.85
0.880.990.840.770.990.710.970.97-0.91-0.810.490.930.950.510.680.990.630.94-0.210.840.650.380.990.920.99
0.730.660.840.740.660.010.720.64-0.34-0.960.370.440.640.930.120.650.940.87-0.480.920.650.160.660.80.66
0.680.490.240.340.310.370.260.46-0.51-0.270.390.510.440.110.390.50.160.280.710.340.380.160.310.340.49
0.850.980.870.81.00.670.980.96-0.88-0.820.420.90.940.490.660.980.610.94-0.30.840.990.660.310.920.98
0.90.910.940.780.920.510.960.92-0.77-0.930.60.80.940.70.620.90.760.96-0.260.930.920.80.340.920.91
0.921.00.840.810.980.680.950.97-0.91-0.810.460.930.950.50.671.00.610.93-0.130.850.990.660.490.980.91
Click cells to compare fundamentals

Repare Therapeutics Account Relationship Matchups

Repare Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Common Stock Shares Outstanding36.7M36.9M37.8M41.9M42.1M35.7M
Total Assets102.7M357.1M368.7M364.1M253.9M267.7M
Other Current Liab4K5.3M16.9M19.5M21.7M11.7M
Total Current Liabilities4.2M11.0M35.1M78.6M39.1M31.2M
Total Stockholder Equity(46.1M)286.8M288.4M279.5M212.1M183.0M
Other Liab8.1M55.9M39.6M2.7M3.1M2.9M
Net Tangible Assets(46.1M)286.8M288.4M279.5M321.4M173.0M
Property Plant And Equipment Net3.4M8.6M13.1M9.6M7.5M8.1M
Net Debt(93.7M)(322.2M)(327.1M)(154.1M)(107.9M)(113.3M)
Retained Earnings(49.9M)(103.4M)(210.3M)(239.3M)(333.1M)(316.5M)
Accounts Payable2.1M2.3M2.3M461K2.4M2.0M
Cash94.8M326.2M334.4M159.5M111.3M190.1M
Non Current Assets Total4.1M10.5M17.3M10.1M10.2M9.9M
Non Currrent Assets Other567K500K586K497K2.7M2.8M
Other Assets699K1.9M4.2M497K571.6K543.0K
Cash And Short Term Investments94.8M333.7M341.9M343.9M223.6M247.3M
Net Receivables3.1M6.2M3.2M4.3M15.3M16.1M
Liabilities And Stockholders Equity102.7M357.1M368.7M364.1M253.9M267.7M
Non Current Liabilities Total144.6M59.2M45.2M5.9M2.7M2.6M
Capital Lease Obligations1.1M4.0M7.3M5.4M3.4M3.9M
Other Current Assets719K6.7M6.3M5.7M4.7M4.5M
Other Stockholder Equity3.8M5.9M18.0M37.2M61.8M64.9M
Total Liab148.8M70.3M80.3M84.6M41.8M61.6M
Net Invested Capital(46.1M)286.8M288.4M279.5M212.1M183.0M
Property Plant And Equipment Gross3.4M8.6M13.1M9.6M14.8M9.4M
Total Current Assets98.6M346.6M351.4M354.0M243.7M257.8M
Net Working Capital94.3M335.5M316.3M275.4M204.6M226.7M
Property Plant Equipment3.4M8.6M5.6M9.6M11.0M6.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Repare Stock Analysis

When running Repare Therapeutics' price analysis, check to measure Repare Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repare Therapeutics is operating at the current time. Most of Repare Therapeutics' value examination focuses on studying past and present price action to predict the probability of Repare Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repare Therapeutics' price. Additionally, you may evaluate how the addition of Repare Therapeutics to your portfolios can decrease your overall portfolio volatility.